Theralink Technologies, Inc.
THER · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -2,997.41% | -489.52% | -532.08% | -836.52% |
| EV / EBITDA | -7.58 | -7.75 | -7.74 | -3.58 |
| Quality | ||||
| ROIC | 6.23% | -0.68% | -0.68% | 11.11% |
| Gross Margin | 77.74% | 75.26% | 75.26% | 85.02% |
| Cash Conversion Ratio | -0.16 | -0.17 | -0.17 | 0.20 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.25% | 19.14% | 46.75% | 67.56% |
| Free Cash Flow Growth | -120.44% | 0.00% | 56.97% | -79.91% |
| Safety | ||||
| Net Debt / EBITDA | -7.55 | -7.65 | -7.65 | -3.48 |
| Interest Coverage | -0.46 | -0.38 | -0.39 | -0.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,759.88 | -2,026.34 | -2,026.34 | -2,248.65 |